The invention provides antibodies and fragments thereof which bind to human Nav1.7, as well as nucleic acids, vectors, host cells and hybridomas for making the same. Further provided are pharmaceutical compositions for use in treating, preventing and/or reducing the risk of a NAV1.7-mediated conditions or diseases, such as pain, inflammation, and metabolic/chronic diseases. The invention additionally provides methods of generating an antibody against a NAV protein of interest.
